Vax drive must target people not yet infected with COVID: AIIMS Professor

The US Centers for Disease Control and Prevention also observed that natural infection provides better and longer protection
Representational image (Picture: Express)
Representational image (Picture: Express)

Vaccination and natural infection both boost herd immunity against COVID, but people who remain uninfected yet are more at risk, thus inoculating them is of utmost importance, said an AIIMS professor.

New variants of COVID-19 have been emerging consistently for the last two years and the vaccine drive is on with the same intensity to mitigate the infection and other severity brought in. While vaccines are a priority for the susceptible population, natural infection also helps to boost immunity just like vaccines.

"Vaccine is the smart way of controlling diseases. However, in the current scenario, those who have recovered from a COVID infection are the best protected people, so vaccinate such people first, who are not COVID infected," said Dr Sanjay Kumar Rai, Professor, Department of Community Medicine, AIIMS, New Delhi, at a weekly health show by the New Delhi-based HEAL Foundation.

Recently, the US Centers for Disease Control and Prevention also observed that natural infection provides better and longer protection. Several studies also prove that one may develop lifelong immunity after a natural infection.

Rai said that "vaccination and natural infection will provide herd immunity. Natural immunity provides a better and longer duration of protection."

Further, to observe the efficacy of vaccines, Rai suggested making two comparator groups for vaccination — one who recovered from COVID and another who are uninfected.

"Universal vaccination is completely irrational as there is no additional benefit. It is unethical because the risk is more than the benefit. Now, there is sufficient evidence that those who have recovered from COVID are the best protected on Earth," Rai noted, emphasising the need for judicious use of vaccines.

"Currently, 334 vaccines for Coronavirus are in different stages of development (140 in clinical trials and 194 in pre-clinical stages) and 33 vaccines are approved for full use," said Rai. 

"Vaccines are effective in preventing severity and death up to 80-90 per cent in a susceptible population. More than 60 per cent of the population around the world have received their first dose of COVID vaccines," he noted.

Related Stories

No stories found.
X
logo
EdexLive
www.edexlive.com